Anti-RIP2/RIPK2 Antibody Picoband®

Overview

Anti-RIP2/RIPK2 Antibody Picoband® is an antibody targeting RIPK2. Common applications include WB, IHC, Flow Cytometry, ELISA. Key specifications include host: Rabbit; clonality: Polyclonal; isotype: Rabbit IgG; reactivity: Human,Mouse,Rat; observed MW: 61 kDa; calculated MW: 61195 MW.

Boster Bio Anti-RIP2/RIPK2 Antibody catalog # PA1861. Tested in WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Target: RIPK2 — Receptor-interacting serine/threonine-protein kinase 2
• Antibody format: Host: Rabbit; Clonality: Polyclonal; Isotype: Rabbit IgG
• Species reactivity: Human,Mouse,Rat
• Molecular weight guidance: Observed: 61 kDa; Calculated: 61195 MW

Specificity note: No cross reactivity with other proteins.

Biological background

Protein function (datasheet): Serine/threonine/tyrosine kinase that plays an essential role in modulation of innate and adaptive immune responses. Upon stimulation by bacterial peptidoglycans, NOD1 and NOD2 are activated, oligomerize and recruit RIPK2 through CARD-CARD domains. Contributes to the tyrosine phosphorylation of the guanine exchange factor ARHGEF2 through Src tyrosine kinase leading to NF-kappaB activation by NOD2. Once recruited, RIPK2 autophosphorylates and undergoes 'Lys-63'-linked polyubiquitination by E3 ubiquitin ligases XIAP, BIRC2 and BIRC3. The polyubiquitinated protein mediates the recruitment of MAP3K7/TAK1 to IKBKG/NEMO and induces 'Lys-63'-linked polyubiquitination of IKBKG/NEMO and subsequent activation of IKBKB/IKKB. In turn, NF-kappa-B is released from NF-kappa-B inhibitors and translocates into the nucleus where it activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Plays also a role during engagement of the T-cell receptor (TCR) in promoting BCL10 phosphorylation and subsequent NF-kappa-B activation. .

Scientific background (datasheet): RIPK2 (Receptor-interacting serine/threonine-protein kinase 2), also known as CARD3, CARDIAK, RICK, RIP2, is an enzyme that in humans is encoded by the RIPK2 gene. It has 540-amino acid protein in length. Northern blot analysis revealed that RICK is expressed in various human tissues as 2.5- and 1.8-kb mRNAs that differ due to alternative polyadenylation. RICK is a novel kinase that may regulate apoptosis induced by the FAS receptor pathway. This gene encodes a member of the receptor-interacting protein (RIP) family of serine/threonine protein kinases. The encoded protein contains a C-terminal caspase recruitment domain (CARD), and is a component of signaling complexes in both the innate and adaptive immune pathways. It is a potent activator of NF-kappa B and inducer of apoptosis in response to various stimuli, CARDIAK (CARD-containing ICE-associated kinase) specifically interacted with the CARD of ICE/caspase-1, and this interaction correlated with the processing of pro-caspase-1 and the formation of the active caspase-1 p20 subunit.

Cellular localization (datasheet): Cytoplasm .

Tissue details (datasheet): Detected in heart, brain, placenta, lung, peripheral blood leukocytes, spleen, kidney, testis, prostate, pancreas and lymph node.

Sequence similarities (datasheet): Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.

Research relevance and current trends

• Commonly studied in contexts related to Apoptosis,Cancer,Caspases,Cell Biology,Cell Death,Immunology,Innate Immunity,Intracellular,Invasion/Microenvironment,Kinases,Metabolism,Obesity,Protein Phosphorylation,Receptors,Ser/Thr Kinases,Signal Transduction,TLR Signaling.
• Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
• Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).

Common research applications

• Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
• ELISA: Measure target abundance in compatible matrices using a standard-curve readout; ensure dilution linearity and appropriate controls.
• Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
• Flow cytometry: Quantify target-positive populations in single-cell suspensions; pair with viability and isotype/FMO controls conceptually.

Notes for experimental interpretation

• Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
• Cross-reactivity (datasheet): No cross-reactivity with other proteins
• Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.

As a polyclonal antibody, this reagent may recognize multiple epitopes on the target, which can improve detection robustness but may require careful specificity controls.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.